INTEGRATIIVINEN LÄÄKETIEDE EUROOPASSA


European Society of Integrative Medicine

Lue lisää


http://www.cam-europe.eu

Lue lisää


http://www.camdoc.eu

Lue lisää


KESKUSTELU

Facebook:
Täydentävät terveysnäkemykset

Blogi:
Täydentävät terveysnäkemykset


UUTUUSKIRJAT

Peter Heusser:
"Kehittyvä ihmiskuva ja tiede"

Tiedote (pdf)

Osa I: Tietoteoreettista pohdintaa

Osa II: Antropologista pohdintaaLue lisää

INTEGRATIIVINEN LÄÄKETIEDE MAAILMALLA


International Society for Complimentary Medicine Research

Lue lisää


Academic Consortium for Integrative Medicine and Health

Lue lisää


Academy of Integrative Health and Medicine

Lue lisää


TUTKIMUS

DATABASE

Peer-reviewed Journals of Research in Integrative Medicine and CAM

Lue lisää.


TULEVAT TAPAHTUMAT

Lue lisää

Keskustelua ja blogit integratiivisen lääketieteen alalla

Ajankohtaista

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. Skyler B. Johnson, Henry S. Park, Cary P. Gross et al. James B. JAMA Oncol. Published online July 19, 2018. doi:10.1001/jamaoncol.2018.2487 https://jamanetwork.com/journals/jamaoncology/article-abstract/2687972

In a retrospective observational study with data from the National Cancer Database on 1 901 815 patients diagnosed with nonmetastatic breast, prostate, lung, or colorectal cancer were investigated whether the use of complementary medicine (CM) was associated with adherence to conventional cancer treatment (CCT) and overall survival. Use of CM was defined as “Other-Unproven: Cancer treatments administered by nonmedical personnel” in addition to at least 1 CCT modality, defined as surgery, radiotherapy, chemotherapy, and/or hormone therapy. Statistical analysis of the data of 258 patients in the CM group and 1 901 557 patients in the control group (no CM used) showed that the CM group were more likely to refuse other conventional cancer treatment and had a higher risk of death than no complementary medicine.

Comment (Peter Zimmermann, MD PhD): The CM group was very small compared to controls and characterized only patients who admitted their use of CM. A significant number of silent CM users may hide in both groups. In addition, many CM users chose CM because they experience more side effects from CCT compared than others. This may also may influence survival. Basic knowledge and training of oncologists in at least some of the evidence based CM modalities would be beneficial to allow the integration of CM into CCT in an individually patient tailoired way. So patients would not have to chose between CM and CCT but rather could use both.

Facebook:
Täydentävät terveysnäkemykset

Blogi:
Täydentävät terveysnäkemykset

Uusimmat aiheet